Cliff Asness’s Quince Therapeutics QNCX Stock Holding History

Cliff Asness’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-62	Closed	-$77K	–	2276
2022 Q1	$77K	Buy	+62	New	+$84.4K	﹤0.01%	2157

Other funds holding QNCX

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

PHAM

Pacific Heights Asset Management San Francisco, California $3.16B AUM 42.38% 1-Year Est. Return

Cliff Asness's QNCX Position: Q2 2022 in Review

Cliff Asness sold out of Quince Therapeutics (QNCX) in Q2 2022, closing a stake of 62 shares — an estimated $77K sold.

Cliff Asness first reported a position in QNCX in Q1 2022 and held it in 1 quarter. The position peaked at $77K in Q1 2022. 66 funds tracked by Wall St. Rank hold QNCX as of Q2 2022.

Cliff Asness reported no remaining Quince Therapeutics position as of Q2 2022 after selling out during the quarter.
Cliff Asness sold 62 Quince Therapeutics shares in Q2 2022, an estimated $77K.
Cliff Asness first reported a position in Quince Therapeutics in Q1 2022 and held it in 1 quarter.
Cliff Asness's Quince Therapeutics position peaked at $77K in Q1 2022.
66 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2022.

Based on AQR Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.